Search results for "IBA"

showing 10 items of 1355 documents

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohor…

2015

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the i…

Genetics and Molecular Biology (all)MaleChronic HepatitisHepacivirusRibavirin/adverse effectsAsthenia/chemically inducedHepacivirusPolyethylene GlycolBiochemistryPolyethylene GlycolsBody Mass IndexChronic Liver Disease0302 clinical medicineNeutropenia/chemically inducedInterferon-alpha/adverse effectsMedicineChroniclcsh:ScienceLiver Diseasesvirus diseasesAntiviral Agents/adverse effectsCohortScience & Technology - Other Topics030211 gastroenterology & hepatologyDrug Therapy CombinationCohort studyHumanmedicine.medical_specialtyAlpha interferonGastroenterology and HepatologyAntiviral AgentsMicrobiologyDose-Response Relationship03 medical and health sciencesPharmacotherapyHepatitis C Chronic/drug therapyDose Prediction MethodsDrug TherapyAnemia/chemically inducedHumansHemoglobinAgedMedicine and health sciencesBiochemistry Genetics and Molecular Biology (all)HepaciviruScience & TechnologyDose-Response Relationship DrugFlaviviruseslcsh:ROrganismsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseaseschemistryAgricultural and Biological Sciences (all)Withholding TreatmentAstheniaImmunologyProportional Hazards Modellcsh:QHuman medicineRNA virusesPhysiologylcsh:MedicinePeginterferon-alfaPolyethylene Glycols/adverse effectsAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Agricultural and Biological Sciences (all); Biochemistry Genetics and Molecular Biology (all); Medicine (all)Cohort Studieschemistry.chemical_compoundOutcome Assessment Health CareMedicine and Health Sciences030212 general & internal medicineViralPathology and laboratory medicineMultidisciplinarybiologyHepatitis C virusPharmaceuticsMedicine (all)AnemiaHepatitis CHematologyRecombinant ProteinOutcome Assessment (Health Care)/methodsMiddle AgedMedical microbiologyHepatitis CRecombinant ProteinsHost-Pathogen InteractionMultidisciplinary SciencesPhysiological ParametersResearch DesignCombinationHost-Pathogen InteractionsVirusesRNA ViralFemaleDrugPathogensHost-Pathogen Interactions/drug effectsResearch ArticleAdultNeutropeniaClinical Research DesignResearch and Analysis MethodsOutcome Assessment (Health Care)Internal medicineRibavirinRecombinant Proteins/adverse effectsRNA Viral/bloodAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding TreatmentAdult; Aged; Anemia; Antiviral Agents; Asthenia; Cohort Studies; Dose-Response Relationship Drug; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Host-Pathogen Interactions; Humans; Interferon-alpha; Male; Middle Aged; Neutropenia; Outcome Assessment (Health Care); Polyethylene Glycols; Proportional Hazards Models; RNA Viral; Recombinant Proteins; Ribavirin; Withholding Treatment; Medicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Proportional Hazards ModelsAntiviral Agentbusiness.industryRibavirinBody WeightHepacivirus/drug effectsViral pathogensInterferon-alphaHepatitis C Chronicbiology.organism_classificationHepatitis virusesMicrobial pathogensRNAAdverse EventsCohort StudiebusinessPloS one
researchProduct

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

2017

Background Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-used all-DAA combinations to evaluate their mode of action and cytotoxicity compared with telaprevir (TVR)+PR. Study design Mathematical modeling of ALT and HCV-RNA kinetics was performed in 111 HCV-1 cirrhotic patients, 81 treated with all-DAA regimens and 30 with TVR+PR. Kinetic-models and Cox-analysis were used to assess determinants of ALT-decay and normalization. Results HCV-RNA kinetics was biphasic, reflecting …

Genetics and Molecular Biology (all)SimeprevirMaleHepacivirusHepacivirusPharmacologyBiochemistryStiffness0302 clinical medicineAnimal CellsMedicineAmino Acidslcsh:ScienceAlanineOrganic CompoundsLiver Diseases3. Good healthCirrhosisPhysical SciencesAdministrationInterferon030211 gastroenterology & hepatologyDrug Therapy CombinationCellular TypesOligopeptidesHumanOralMaterials ScienceGastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesDrug TherapyHumansAgedKineticPharmacologyHepaciviruBiochemistry Genetics and Molecular Biology (all)Mathematical Modelinglcsh:RChemical CompoundsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseasesAdministration Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; RNA Viral; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)030104 developmental biologyAgricultural and Biological Sciences (all)chemistryAliphatic Amino Acidslcsh:Q0301 basic medicineSofosbuvirlcsh:MedicineAdministration OralMedicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Viral Nonstructural ProteinsTelaprevirchemistry.chemical_compoundSimeprevirMedicine and Health SciencesViralMultidisciplinarybiologyAntimicrobialsMedicine (all)Simulation and ModelingDrugsAlanine TransaminaseHepatitis CMiddle AgedAntiviralsHepatitis CChemistryTreatment OutcomeLiverCombinationOligopeptideRNA ViralFemaleAnatomymedicine.drugResearch ArticleSettore MED/17 - Malattie InfettiveGeneral Science & TechnologyMaterial PropertiesResearch and Analysis MethodsMicrobial ControlVirologyRibavirinMechanical PropertiesNS5AAntiviral Agentbusiness.industryRibavirinHCV DAA ALTViral Nonstructural ProteinOrganic ChemistryCell Biologybiology.organism_classificationKineticsAlanine transaminaseAdministration Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; RNA Viral; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteinsbiology.proteinHepatocytesRNAInterferonsSofosbuvirbusiness
researchProduct

Real-time PCR detection of Pseudomonas aeruginosa in clinical and municipal wastewater and genotyping of the ciprofloxacin-resistant isolates

2006

Real-time quantification of Pseudomonas aeruginosa was performed in various wastewater systems including clinical, municipal wastewaters and inflow from a wastewater treatment plant. The highest concentrations of P. aeruginosa-specific targets were detected in clinical wastewaters. Limitations of the detection system resulting from inhibition or cross-reaction were identified. Ciprofloxacin-resistant P. aeruginosa strains were isolated after specific enrichment from clinical and municipal wastewaters. In some cases they were also cultivated from effluent of a wastewater treatment plant, and from its downstream river water. A total of 119 isolates were phenotypically characterized as ciprofl…

GeneticsEcologyPseudomonas aeruginosabiochemical phenomena metabolism and nutritionRibosomal RNABiologybacterial infections and mycosesmedicine.disease_causebiology.organism_classificationApplied Microbiology and BiotechnologyMicrobiologyDNA gyraseMicrobiologyCiprofloxacinGenotypemedicineGenotypingAntibacterial agentmedicine.drugPseudomonadaceaeFEMS Microbiology Ecology
researchProduct

Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin

2008

We present an analysis of the selective forces acting on two hepatitis C virus genome regions previously postulated to be involved in the viral response to combined antiviral therapy. One includes the three hypervariable regions in the envelope E2 glycoprotein, and the other encompasses the PKR binding domain and the V3 domain in the NS5A region. We used a cohort of 22 non-responder patients to combined therapy (interferon alpha-2a plus ribavirin) for which samples were obtained before initiation of therapy and after 6 or/and 12 months of treatment. A range of 25-100 clones per patient, genome region and time sample were sequenced. These were used to detect general patterns of adaptation, t…

Genome evolutionHepatitis C virusEvolutionary Biology/Bioinformaticslcsh:MedicineAlpha interferonGenome ViralHepacivirusBiologyVirology/Immune EvasionInterferon alpha-2Viral Nonstructural Proteinsmedicine.disease_causeGenomeAntiviral AgentsEvolution Molecularchemistry.chemical_compoundGenetics and Genomics/Population GeneticsRibavirinmedicineHumanslcsh:ScienceNS5APhylogenyGenetics:CIENCIAS DE LA VIDA::Genética ::Otras [UNESCO]Virology/Antivirals including Modes of Action and ResistanceMultidisciplinaryEvolutionary Biology/Evolutionary and Comparative GeneticsHepatitis C virusRibavirinlcsh:RGenetic VariationInterferon-alphaVirologyComplementarity Determining RegionsHepatitis CVirology/Virus Evolution and SymbiosisRecombinant ProteinsUNESCO::CIENCIAS DE LA VIDA::Genética ::OtrasHypervariable regionchemistryViral evolutionInterferonlcsh:QGenetic variabilityHepatitis C virus; Genetic variability; Interferon; Ribavirin; Combined therapyCombined therapyResearch ArticlePLoS ONE
researchProduct

Análisis coste-utilidad de la triple terapia con telaprevir en pacientes con hepatitis C no tratados previamente

2014

Introducción: En España, con una prevalencia del 2,5%, la hepatitis C (VHC) se asocia a una elevada morbi-mortalidad. El tratamiento combinado de telaprevir y peginterferon/ribavirina ([T/PR]) es eficaz en pacientes con VHC-G1. El objetivo primario de este estudio fue evaluar la relación coste-utilidad (RCUI) de [T/PR] versus peginterferon alfa 2a/ribavirina ([PR]) en pacientes naïve VHC-G1, según el grado de fibrosis y bajo la perspectiva del sistema sanitario español. Metodología: La eficacia y la incidencia de efectos adversos (EAs) se obtuvieron de los estudios ADVANCE y OPTIMIZE. La estimación de los costes de monitorización, de manejo de EAs y de la enfermedad por estados de salud (€,…

Genotipo 1Coste-utilidadRibavirinaPeginterferon alfa 2aHepatitis CTelaprevir
researchProduct

Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combine…

2003

ISDR mutation pattern and HVR-1 quasispecies were analyzed in HCV genotype 1b-infected patients treated with either PEG- or STD-IFN plus ribavirin, in order to find virological correlates of therapy outcome. ISDR region analysis, performed at baseline (T0) and at 4 weeks of therapy (T1), indicated that ISDR mutation pattern was not predictive of response to treatment. Moreover, no selection of putative resistant strains in the first month of therapy was observed. Viral load was not correlated with any parameter of HVR-1 heterogeneity. Among the HVR-1 heterogeneity parameters considered, complexity was inversely correlated to viral load decline at T1. In univariate analysis, complexity, prop…

GenotypeHepacivirusInterferon alpha-2Viral Nonstructural ProteinsAntiviral AgentsPolyethylene GlycolsViral ProteinsGenetic HeterogeneityRibavirinHumansViral ProteinPhylogenyAntiviral AgentHepaciviruViral Nonstructural ProteinInterferon-alphaSequence Analysis DNAHepatitis C ChronicRecombinant ProteinViral LoadRecombinant ProteinsTreatment OutcomeLinear ModelsLinear ModelDrug Therapy CombinationSequence AlignmentHuman
researchProduct

Optimal therapy in hepatitis C virus genotypes 2 and 3 patients.

2011

Current guidelines recommend that patients with genotype 2 (G2) and 3 (G3) chronic hepatitis C be treated with pegylated interferon (PEG-IFN) plus low doses of ribavirin (800 mg/day) for 24 weeks, resulting in a sustained virological response (SVR) rate of approximately 80%. Considering these high response rates, several recent randomized trials have assessed whether shorter treatment (12-16 weeks) could be cost-effective in these patients. The results of these studies vary but suggest better responsiveness in G2 patients, and overall, do not strongly support reducing treatment to G3, viral load < 400 000 IU, low fibrosis, no metabolic cofactors), shorter treatment is as effective as standa…

GenotypeInterleukinsInterferon-alphaStandard of CareHepacivirusInterferon alpha-2Antiviral AgentsHepatitis CPolymorphism Single NucleotideRecombinant ProteinsPolyethylene GlycolsRibavirinhcvHumansInterferonsLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?

2009

The recommended treatment duration with pegylated interferon-α plus ribavirin for patients infected with hepatitis C virus (HCV) genotype 1 is 48 weeks. Interestingly, a subpopulation of genotype 1 patients experience rapid decreases in HCV RNA levels once treatment is initiated and attain rapid virological response, defined as undetectable HCV RNA at week 4 of therapy. Several studies have shown that these patients can be effectively treated for a 24-week period without any significant decreases in sustained virological response rates. The aim of this review was to consider the existing clinical evidence regarding the use of a 24-week treatment schedule among genotype 1 patients and to hi…

GenotypeTreatment durationHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsDrug Administration SchedulePolyethylene Glycolschemistry.chemical_compoundPegylated interferonGenotypeRibavirinMedicineHumansPharmacology (medical)In patientPharmacologyClinical Trials as Topicbusiness.industryRibavirinInterferon-alphaHepatitis CHepatitis C Chronicmedicine.diseaseVirologyRecombinant ProteinsInfectious DiseasesTreatment OutcomechemistryHCVDrug Therapy Combinationbusinessmedicine.drugAntiviral therapy
researchProduct

Pagine di geografia, pagine di vita

2020

Il capitolo analizza una parte della produzione scientifica di Girolamo Cusimano, professore ordinario di Geografia presso l'Università di Palermo. In particolare, attraverso una selezione di testi significativi, vengono ripercorsi sia il posizionamento dello studioso nel dibattito sul complesso rapporto tra paesaggio e letteratura in seno alla Geografia umana e culturale tra la fine degli anni Novanta e l'inizio degli anni Duemila, sia il suo contributo alla discussione teorica sulla cartografia.

Geografia culturale Geografia umana Paesaggio Letteratura Dibattito teorico CartografiaSettore M-GGR/01 - Geografia
researchProduct

Dagli anni ruggenti dell’«Ora». I dibattiti sul Gattopardo

2019

Il saggio ricostruisce il dibattito che si svolse, sapientemente orchestrato dal suo memorabile Direttore Vittorio Nisticò, sul giornale "L'Ora", subito dopo la pubblicazione del "Gattopardo". A porre le basi della discussione è Leonardo Sciascia la cui polemica si appunta sul modo di leggere la storia della Sicilia per poi vedere avvicendarsi le voci di scrittori giornalisti intellettuali. Ne risulta la vitalità culturale di un quotidiano che seppe coniugare denuncia e cultura. Tale linea editoriale viene ulteriormente confermata dal secondo dibattito che si svolse a dieci anni della pubblicazione del romanzo. A fare un bilancio sul successo furono chiamati insieme a Sciascia, che attenua …

Giornalismo quotidiano Nisticò dibattito Gattopardo successo SiciliaSettore L-FIL-LET/11 - Letteratura Italiana Contemporanea
researchProduct